ClinicalTrials.gov record
Active, not recruiting No phase listed Observational

A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid Tumors

ClinicalTrials.gov ID: NCT05812027

Public ClinicalTrials.gov record NCT05812027. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Apr 29, 2026, 12:44 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Screening Study to Determine HLA Type, HLA Loss of Heterozygosity Status and Tumor Antigen Expression in Participants With Locally Advanced (Unresectable) or Metastatic Solid Tumors

Study identification

NCT ID
NCT05812027
Recruitment status
Active, not recruiting
Study type
Observational
Phase
Not listed
Lead sponsor
TScan Therapeutics, Inc.
Industry
Enrollment
1,150 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 25, 2023
Primary completion
Dec 31, 2025
Completion
Jan 13, 2027
Last update posted
Nov 16, 2025

2023 – 2027

United States locations

U.S. sites
21
U.S. states
16
U.S. cities
20
Facility City State ZIP Site status
HonorHealth Research and Innovation Institute Scottsdale Arizona 85258
University of California San Diego San Diego California 92037
Yale Cancer Center New Haven Connecticut 06510
Memorial Healthcare System Hollywood Florida 33021
University of Miami, Sylvester Comprehensive Cancer Center Miami Florida 33136
Orlando Health Orlando Florida 32806
University of South Florida Tampa Florida 33606
University of Chicago Chicago Illinois 60637
Norton Cancer Institute Louisville Kentucky 40202
Karmanos Cancer Institute Detroit Michigan 48201
University of Minnesota, Masonic Cancer Center Minneapolis Minnesota 55455
Columbia University Herbert Irving Comprehensive Cancer Center New York New York 10032
University of North Carolina at Chapel Hill Chapel Hill North Carolina 27599
Oncology Hematology Care Cincinnati Ohio 45242
The Cleveland Clinic Cleveland Ohio 44195
OU Health Stephenson Cancer Center Oklahoma City Oklahoma 73104
Providence Cancer Institute Franz Clinic Portland Oregon 97213
Allegheny Hospitals Network Pittsburgh Pennsylvania 15224
University of Pittsburgh Medical Center Pittsburgh Pennsylvania 15232
Sarah Cannon Research Institute Nashville Tennessee 37203
Baylor College of Medicine Houston Texas 77030

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05812027, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 16, 2025 · Synced Apr 29, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05812027 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →